{
  "docId": "019de074-cfba-73af-96cf-2b33e6c699c9",
  "docSlug": "90ad9e76f71a7983fe14e2a7d36252ee",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 28,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 20,
  "notes": "Includes a line chart for efficacy over time and two bar charts for pharmacokinetic concentrations in plasma vs liver.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-cfba-73af-96cf-2b33e6c699c9/21",
  "deckHref": "/decks/019de074-cfba-73af-96cf-2b33e6c699c9",
  "deckJsonHref": "/decks/019de074-cfba-73af-96cf-2b33e6c699c9.json",
  "deckAnchorHref": "/decks/019de074-cfba-73af-96cf-2b33e6c699c9#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.2,
        "x": 0.45,
        "y": 0.45
      },
      "kind": "chart",
      "text": "Fraction Unbound Concentrations (C24h) [AB-161]free: plasma",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "112c7ffe-0bf1-4831-8618-996661384959",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.7,
        "y": 0.45
      },
      "kind": "chart",
      "text": "Fraction Unbound Concentrations (C24h) [AB-161]free: liver",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "142b5f12-8ef7-42d2-b3c4-d25a5a32b45c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.07,
        "y": 0.45
      },
      "kind": "chart",
      "text": "AAV-HBV mouse AB-161 QD for 14 days",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72ad9a97-6005-4f9a-886a-4a0a6340d1b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.07,
        "y": 0.18
      },
      "kind": "list",
      "text": "AB-161 effective as a once-daily dose in AAV-HBV mouse model (0.3, 1, 10, 30 mg/kg QD)\nDose-dependent reduction of HBsAg, also observed with BID dosing (0.3 and 1 mg/kg BID)\nHBsAg reduction achieved when fraction unbound C24h > EC90 in liver",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e768fbff-9ea4-421a-a5c5-a5bd9415c74c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.15,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Data presented at Discovery on Target Conference, October 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f4823ef-d3b2-4240-90fe-8ace9206f20e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "Compound concentration in liver drives efficacy",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7771aeda-d6c1-4509-9687-cc2dd838345e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "AB-161 Reduces HBsAg in AAV-HBV Mouse Model",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29543b00-60e5-4294-ba31-924c31c4dc3d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 3,
      "beatId": "708d5cbd-cd14-4361-ab43-54fc6ba4b110",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Our Strategy, Broad Pipeline, AB-729 RNAi Therapeutic, and other solution-focused slides",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}